Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
90 studies found for:    coronado
Show Display Options
Rank Status Study
1 Not yet recruiting TSO for Plaque Psoriasis
Condition: Plaque Psoriasis
Intervention: Biological: Trichuris Suis Ova
2 Active, not recruiting Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure
Condition: Acute Alcoholic Hepatitis
Interventions: Biological: ELAD  treatment;   Other: Standard of care (Control)
3 Unknown  Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Condition: Crohn's Disease
Interventions: Biological: Trichuris suis ova (TSO);   Biological: Placebo
4 Active, not recruiting Trichuris Suis Ova in Autism Spectrum Disorders
Condition: Autism
Intervention: Drug: Trichuris Suis Ova
5 Terminated Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis
Condition: Nonalcoholic Steatohapatitis
Interventions: Drug: Roflumilast;   Drug: Pioglitazone;   Drug: Placebo
6 Completed
Has Results
Safety and Tolerability of Single Doses Oral CNDO 201 Trichuris Suis Ova in Patients With Crohn's Disease
Condition: Crohn's Disease
Interventions: Biological: Trichuris suis ova;   Other: Placebo
7 Recruiting Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder
Condition: Autism
Interventions: Biological: Trichuris suis ova;   Other: Placebo
8 Recruiting CNDO-109-AANK for AML in First Complete Remission (CR1)
Condition: Acute Myeloid Leukemia
Intervention: Biological: CNDO-109-AANK Cells
9 Recruiting Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
Conditions: Acute Episode of Overt Hepatic Encephalopathy;   Hepatic Encephalopathy
Interventions: Drug: ornithine phenylacetate;   Drug: placebo intravenous infusion
10 Active, not recruiting Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
Condition: Hepatitis C
Intervention: Drug: Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)
11 Recruiting Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure
Condition: Thrombocytopenia Associated With Liver Disease
Interventions: Drug: avatrombopag (lower baseline platelet count);   Drug: placebo (lower baseline platlet count);   Drug: avatrombopag (higher baseline platelet count);   Drug: placebo (higher baseline platelet count)
12 Completed
Has Results
Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients
Condition: Hepatitis C Virus
Interventions: Drug: Sofosbuvir;   Drug: Placebo to match sofosbuvir;   Drug: PEG;   Drug: RBV
13 Completed A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis
Condition: Hepatitis C, Chronic
Interventions: Drug: RO5024048;   Drug: danoprevir;   Drug: peginterferon alfa-2a [Pegasys];   Drug: ribavirin;   Drug: ritonavir
14 Completed Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care
Condition: Chronic Hepatitis C
Interventions: Drug: BMS-790052;   Drug: BMS-650032;   Drug: Pegylated-interferon alfa-2a;   Drug: Ribavirin
15 Completed A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Condition: Hepatorenal Syndrome Type 1
Interventions: Drug: Terlipressin;   Drug: Placebo
16 Recruiting A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection
Conditions: Chronic Hepatitis C;   Hepatitis C Virus;   HCV
Interventions: Drug: ABT-493;   Drug: ABT-530
17 Completed
Has Results
An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients
Condition: Hepatitis C
Interventions: Drug: Placebo;   Drug: TMC435;   Drug: Peginterferon alpha-2a (PegIFN alpha-2a);   Drug: Ribavirin (RBV)
18 Completed The Safety/Efficacy Of Rifaximin With/Without Lactulose In Subjects With A History Of Recurrent Hepatic Encephalopathy
Conditions: Hepatic Encephalopathy;   Cirrhosis
Interventions: Drug: Rifaximin;   Drug: Rifaximin and Lactulose
19 Completed
Has Results
Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection
Condition: Chronic Hepatitis C
Interventions: Drug: Sofosbuvir;   Drug: RBV;   Drug: PEG
20 Completed GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection
Condition: Hepatitis C, Chronic
Interventions: Drug: GS-5885;   Drug: Tegobuvir;   Drug: GS-9451;   Drug: ribavirin tablet

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years